Updates in the Treatment of Secondary AML After the 2024 SOHO Annual Meeting

James K. McCloskey, MD, and Harry P. Erba, MD, PhD, discuss updates in acute myeloid leukemia following the 2024 SOHO Annual Meeting.

EP. 1: The Diagnosis and Prevalence of Secondary AML

October 24th 2024

James K. McCloskey, MD, and Harry P. Erba, MD, PhD, discuss the diagnosis and prevalence of secondary acute myeloid leukemia.

EP. 2: Defining Intensive Chemotherapy Fitness in AML

October 24th 2024

James K. McCloskey, MD, and Harry P. Erba, MD, PhD, discuss factors to help determine intensive chemotherapy fitness in acute myeloid leukemia.

EP. 3: Long-Term Data for CPX-351 in Secondary AML

October 24th 2024

James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss long-term data for CPX-351 in acute myeloid leukemia.

EP. 4: Dose Intensity and Sequencing of Intensive Chemotherapy in Secondary AML

October 24th 2024

James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss dose intensity and sequencing of CPX-351 in secondary acute myeloid leukemia.

EP. 5: Factors When Weighing Intensive Chemotherapy vs Other Regimens in Secondary AML

October 24th 2024

James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss factors for picking intensive chemotherapy vs other regimens in acute myeloid leukemia.

EP. 6: Goals in the Treatment of Secondary AML

October 24th 2024

James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the treatment goals in secondary acute myeloid leukemia.

EP. 7: The Role of Genetic Profiling in Secondary AML

October 24th 2024

James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the role of genomic profiling in secondary acute myeloid leukemia.